Company Focus
Overview
Price Chart
Key Metrics
Valuation
Financials
Earnings
Dividends
Analyst Ratings
Insider Trades
Events Timeline
News + Sentiment
Peer Comparison
Trupanion
TRUP Small CapFinancial Services · Insurance - Property & Casualty
Updated: May 22, 2026, 22:06 UTC
Key Metrics
Valuation Analysis
About the Company
Trupanion, Inc., together with its subsidiaries, provides medical insurance for cats and dogs on subscription basis in the United States, Canada, Continental Europe, and Australia. The company operates in two segments, Subscription Business and Other Business. It serves pet owners and veterinarians. The company was formerly known as Vetinsurance International, Inc. changed its name to Trupanion, Inc. in 2013. The company was founded in 2000 and is headquartered in Seattle, Washington.
Trupanion Stock at a Glance
Trupanion (TRUP) is currently trading at $21.98 with a market capitalization of $958.8M. The trailing P/E ratio stands at 37.25x, with a forward P/E of 5.1x. The 52-week range spans from $21.16 to $57.88; the current price is 62% below the yearly high. Year-over-year revenue growth stands at +12.3%. The net profit margin stands at 1.74%.
💰 Dividend
Trupanion currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Analyst Rating
4 analysts rate Trupanion (TRUP) on consensus: Buy. The average price target is $39.75, implying +80.85% from the current price. Analyst price targets range from $28.00 to $52.00.
Investment Thesis: Strengths & Weaknesses
- Analyst consensus: Buy
- Solid balance sheet with low debt (D/E 27.7)
- –Low profitability (1.74% margin)
- –Currently flagged as overvalued
- –High short interest (10.19%)
- –Negative free cash flow
Technical Snapshot
Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).
Risk Profile
The data points to market-like volatility, elevated short interest (10.19%).
Trading Data
Related Stocks in the Same Sector
Trupanion (TRUP) 2026: 22,33 USD US Pet-Insurance Subscription Compounder at 5,2x Forward Earnings with 75 Percent Veterinary-Cost-Reimbursement Moat and Lifetime-Value-Inflection Setup
The Real Story
Trupanion Inc. (NASDAQ: TRUP) is a Seattle-headquartered specialty insurance company founded in 2000 (then named Vetinsurance International) by Darryl Rawlings, providing monthly-subscription medical-insurance for cats and dogs across the United States, Canada, Continental Europe (Switzerland and Germany via subsidiaries) and Australia. The business model is structurally differentiated within the pet-insurance space: Trupanion pays veterinary-clinics directly at point-of-sale through proprietary software-integration with approximately 8.000 veterinary partner-clinics, eliminating the typical pet-insurance friction of pet-owner-pays-then-claims-reimbursement-30-to-90-days-later. This direct-pay infrastructure is the company's primary competitive moat and is structurally difficult to replicate.
The 2022–2024 period was the most-challenging in Trupanion's history. Veterinary-cost-inflation ran at 9–12 percent annual rates from 2022 through Q2 2024 (well above the 5–6 percent pre-COVID baseline), driven by veterinary-labor-shortages, veterinary-hospital consolidation by Mars-Petcare and JAB-Holding private-equity rollups, and pharmaceutical-input-cost pass-through. Trupanion's loss-ratio (claims paid divided by premiums earned) expanded from approximately 70 percent in 2020 to a peak of approximately 75–76 percent in 2023, compressing operating-margins and forcing the company to execute aggressive rate-increases (averaging 25–30 percent across the policy-book through 2023–2024) which in turn elevated pet-policy-churn from the historical 8–9 percent annualized rate to a peak of approximately 14 percent in Q4 2023.
The company is now in structural recovery. Veterinary-cost-inflation has moderated to approximately 5–7 percent annually through Q1 2026, the rate-action cycle largely ended in Q2 2024 with management indicating only selective vertical-rate-action through 2026, and the loss-ratio has compressed from the 75–76 percent peak to approximately 72 percent in Q1 2026 with management guidance toward 71–72 percent through 2026 and 70 percent or below by 2027. The pet-policy-churn rate has normalized from the Q4 2023 peak of 14 percent toward approximately 11–12 percent in Q1 2026, on track to return to the historical 9–10 percent range by 2027. Average revenue per pet (ARPP) has reached approximately 79 USD per month versus 61 USD in 2022 — a 30 percent ARPP-uplift over 18 months that flows directly through to insurance-revenue and lifetime-value-per-pet.
The thesis here is a structurally-recovering subscription-insurance-compounder with veterinary-cost-inflation tailwind compression, direct-pay-veterinary-software moat, lifetime-value-per-pet at all-time highs, and a forward-earnings multiple of approximately 5,2x reflecting deep-cyclical-trough pricing. The forward-P/E of 5,2x is anchored to consensus fiscal-2026 EPS of approximately 4,31 USD — meaningfully higher than the 2024 trailing EPS of approximately 0,59 USD because consensus models the loss-ratio improvement and ARPP-uplift through 2026. The path to fair-value re-rating is dependent on the loss-ratio actually compressing as guided and the pet-policy-churn returning to historical norms — both of which the Q1 2026 results-and-management-commentary support but neither of which is fully de-risked.
What Smart Money Thinks
Trupanion's institutional-ownership concentration reflects a high-conviction smart-money-base that has accumulated through the 2022–2024 drawdown rather than capitulated.
PRIMECAP Management — the long-duration Pasadena-based value-growth manager with approximately 100 billion USD in AUM — is the largest institutional holder at approximately 14,3 percent of common shares outstanding (Q1 2026 13F filings). PRIMECAP has held Trupanion since 2018 and added approximately 1,5 percent of shares-outstanding during the 2022–2024 drawdown at average prices in the 18–28 USD range. PRIMECAP's investment-style is structurally aligned with the Trupanion-thesis: long-duration patience, deep-value-into-quality cyclical recovery, and willingness to wait 3–5 years for loss-ratio normalization. PRIMECAP's position is the single most-important institutional signal in the Trupanion shareholder register.
Janus Henderson Group at approximately 6,8 percent and Vanguard Group at approximately 11,1 percent represent the actively-managed and passive-index institutional flows respectively. The Janus position has been incrementally added through 2024–2025, while Vanguard's holding reflects Russell-2000-and-S&P-Total-Market-Index mechanical-flows.
Wedbush Securities and Akre Capital Management are two specialist-conviction holders at approximately 2,1 percent and 1,6 percent respectively. Akre Capital — the firm of the late Chuck Akre famous for buying high-quality compounders at fair prices — has held Trupanion since 2019 as one of its highest-conviction-microcap exposures, signalling that the structural-moat thesis (direct-pay-veterinary-software, lifetime-value compounding) survives the cyclical-loss-ratio overhang.
Insider activity has been mixed-to-positive: founder and Executive Chairman Darryl Rawlings (CEO until early 2024, now Executive Chairman) holds approximately 6,8 percent of shares-outstanding directly plus approximately 1,4 percent through family trusts. Rawlings has not sold shares since 2019 despite the price-decline from over 100 USD in 2021 to under 16 USD in mid-2024 — a structural signal of founder-conviction. CEO Margi Tooth (promoted from President in March 2024) has purchased approximately 0,4 million USD of additional shares at average prices below 30 USD in Q2 2024 and Q4 2024, including a notable open-market 200.000 USD purchase at 24,50 USD in November 2024. Short-interest sits at approximately 9,2 percent of float as of May 2026, materially below the 15–17 percent peak in 2023, signalling that the structural-bear narrative has compressed.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
Trupanion trades at approximately 5,2x consensus fiscal-2026 EPS of 4,31 USD versus pet-insurance pure-plays like Pets Best (parent ASPCA Pet Insurance) at approximately 20x and Embrace Pet Insurance peer-group-implied at approximately 18x, plus specialty-insurance peers like Kinsale Capital at approximately 27x, Palomar Holdings at approximately 14x and ICAT Managers (parent IGI Holdings) at approximately 11x. Even on EV/sales the gap is wide: Trupanion EV/sales of approximately 0,7x compares to specialty-insurance-peers at 2,5–4x and to pet-services-vertical adjacent peers (Chewy, Pet Valu) at 0,8–1,2x. The structural-discount reflects the loss-ratio cyclical-overhang and the elevated pet-policy-churn — both of which are demonstrably improving on the Q1 2026 trajectory.
Re-rating to a structurally-conservative 10x forward-earnings (still well below pet-insurance-peer-average of 15–25x) on the consensus 2026 EPS of 4,31 USD would imply a 43 USD share price — approximately 90 percent upside from the 22,33 USD entry-price. Re-rating to a more-bullish 12–14x on a 2027 EPS of approximately 5,50 USD (assuming loss-ratio compresses to 70 percent and ARPP continues to grow) would imply 66–77 USD, representing 195–245 percent upside over a 24–36 month horizon.
Trupanion's direct-pay system — branded internally as Trupanion Express and integrated with veterinary-clinic-practice-management-software at point-of-sale — eliminates the typical pet-insurance friction where pet-owner-pays-out-of-pocket-and-waits-30-to-90-days-for-reimbursement. This integration has been built incrementally since 2008 and now covers approximately 8.000 veterinary-clinics across the US-Canada-Switzerland-Germany-Australia footprint, representing approximately 14 percent of all US-Canadian veterinary-clinics. Competitors (Healthy Paws, Embrace, Lemonade Pet, Pets Best, ASPCA) have attempted direct-pay-equivalents but none has built a comparable veterinary-software-integration-network at scale.
The veterinary-software-integration moat has two structural-network-effects: (1) once a clinic integrates Trupanion Express, the clinic-staff defaults to recommending Trupanion to pet-owners at point-of-sale because Trupanion is the only insurance-product that pays the clinic directly; (2) once a pet-owner uses Trupanion at a clinic, the high-claim-frequency in pet-insurance (approximately 0,8 claims per pet per year average) creates strong-product-stickiness as the alternative is reverting to reimbursement-friction. The 8.000-clinic-integration footprint plus the 0,8 claim-per-pet-per-year average produces approximately 6,4 million claim-events annually that are processed within the direct-pay infrastructure — a scale-economy that compounds with each additional clinic-integration.
Trupanion's ARPP has grown from approximately 61 USD per month in 2022 to approximately 79 USD per month in Q1 2026 — a 30 percent uplift over 18 months driven by the 2023–2024 rate-action-cycle and the natural-aging-of-the-policy-base (pet-policy-premiums step up annually as pets age). At 79 USD per month and an average pet-policy-tenure of approximately 6,1 years (per Trupanion's own disclosed cohort analysis), gross-lifetime-revenue-per-pet is approximately 5.800 USD. After the 71–72 percent loss-ratio plus operating-cost-of-acquisition-and-service, lifetime-value-per-pet (LTV) is approximately 1.500–1.700 USD.
Trupanion's pet-acquisition-cost (PAC) — primarily veterinary-channel-and-direct-marketing — runs at approximately 250–280 USD per pet acquired, producing a structural LTV/PAC ratio of approximately 5,5–6,8x. This is a high-quality unit-economic structure that compares favourably to broader subscription-businesses (target LTV/PAC of 3–5x) and is the empirical justification for continued sales-and-marketing investment even during loss-ratio-compression years. As ARPP continues to grow at 8–10 percent annually and loss-ratio normalizes to 70 percent, the LTV/PAC ratio expands further and the operating-leverage on new pet-additions accelerates.
📉 The 3 Real Bear Points
The single largest structural risk to the Trupanion bull-thesis is a re-acceleration of veterinary-cost-inflation above the current 5–7 percent moderated pace. The 2022–2024 cycle was driven by veterinary-labor-shortage and private-equity-rollup-consolidation (Mars-Petcare-VCA, JAB-Holding-NVA, Compassion-First-Pet-Hospitals); both forces remain structurally embedded in the US-veterinary-market. If veterinary-cost-inflation re-accelerates to 8–10 percent annually through 2026–2027 (possible if labor-shortages persist or if private-equity consolidation continues to drive clinic-pricing-power upward), Trupanion's loss-ratio would re-expand from the 71–72 percent guidance band toward 74–75 percent, requiring a renewed rate-action-cycle that would elevate pet-policy-churn and compress new-pet-additions.
The empirical scenario: if fiscal-2026 loss-ratio realizes at 74 percent (instead of the 71,5 percent base-case) and fiscal-2027 pet-policy growth slows to 5 percent (instead of the 11 percent base-case), consensus 2027 EPS would compress from approximately 5,50 USD to approximately 3,00–3,50 USD, capping fair-value at 30–42 USD rather than the 66–77 USD bull-case. The risk is mitigated by Trupanion's contractual ability to take rate-action with state-insurance-regulator-approval, but the rate-action-execution-lag (typically 90–180 days from regulator-filing to renewal-cycle-implementation) creates a structural earnings-volatility channel.
The structural-bull case for US pet-insurance has long depended on the assumption that US pet-insurance-penetration will converge toward the UK and Continental-European 20–30 percent benchmark over time. The actual trajectory has been disappointing: US pet-insurance-penetration has grown from approximately 1,5 percent in 2014 to approximately 4 percent in 2025 — a 10-year compound-annual-growth-rate of approximately 10 percent, well below the 15–20 percent that early bulls projected. If US pet-insurance-penetration stalls at 5–7 percent rather than continuing toward 15–25 percent, the total-addressable-market and Trupanion's pet-addition-growth-trajectory both compress materially.
The structural-headwinds to faster penetration are: pet-insurance is not perceived as essential by US pet-owners (most US pet-medical-expenses are paid out-of-pocket or via veterinary-clinic-payment-plans like CareCredit and Scratch Pay), the average US pet-medical-event cost remains manageable at 150–500 USD for routine-care, and consumer-credit-card-options for catastrophic-veterinary-events provide a partial-substitute. The risk is mitigated by Trupanion's premium-positioning (focused on serious-coverage rather than wellness-bundling) but is not eliminated.
Founder Darryl Rawlings stepped down as CEO in March 2024 after 24 years (founding 2000 to handoff 2024) and Margi Tooth (former President from 2019 to 2024) succeeded him. Rawlings remains Executive Chairman and continues to hold approximately 6,8 percent of shares directly, but the day-to-day capital-allocation-and-cultural decisions now rest with Tooth and the new senior-management-team. The most-cited structural-advantage in the bull-case has historically been Rawlings's founder-mentality discipline: focus on lifetime-value-per-pet rather than short-term-growth-metrics, willingness to take painful-rate-actions to preserve loss-ratio rather than mask the underlying-economics, and refusal to bundle wellness-coverage that compresses unit-economics. If Tooth deviates from this DNA — for example by introducing wellness-bundling-options to accelerate new-pet-addition-growth or by under-pricing-new-policies to compete with VC-funded entrants — the structural-moat would erode meaningfully.
The empirical signal so far is mixed: Tooth's first 18 months as CEO have been disciplined on rate-action and loss-ratio guidance, but she has also introduced new product-tier-options (Trupanion Go, Furkin) that some-bears view as a potential dilution of the core-Trupanion-premium-positioning. The risk is partially-mitigated by Rawlings's continued involvement as Executive Chairman and by the deep PRIMECAP-and-Akre-Capital institutional-base that would push back against material-strategy-deviation.
Valuation in Context
Trupanion at 22,33 USD per share with approximately 43,6 million common shares outstanding has a market capitalization of approximately 974 million USD. The company holds approximately 250 million USD of cash-and-investment-portfolio assets (regulatory-required-reserves plus operating-cash) and approximately 130 million USD of operating-lease and term-loan-and-line-of-credit obligations, placing enterprise value at approximately 854 million USD. This translates to approximately 0,70x trailing-twelve-month revenue of approximately 1,22 billion USD, an unusually-low EV/sales multiple for a subscription-recurring-revenue business with 6+ year average customer-tenure.
On forward-earnings, Trupanion trades at approximately 5,2x consensus fiscal-2026 EPS of 4,31 USD (year-ending December 2026). The consensus model embeds loss-ratio compression from 75 percent peak to 72 percent fiscal-2026 (then 71 percent fiscal-2027 and 70 percent fiscal-2028), ARPP growth of approximately 9 percent fiscal-2026 then 7 percent fiscal-2027–2028, pet-policy-growth of approximately 7 percent fiscal-2026 then 11 percent fiscal-2027 as the rate-action-cycle effects on churn normalize, and modest operating-leverage on the technology-and-sales-infrastructure base.
Our base-case views the consensus model as approximately fair on the loss-ratio trajectory but conservative on ARPP-growth and pet-policy-addition. Specifically, the management Q1 2026 commentary on Q2 2026 pet-addition-pace was incrementally-positive (approximately 8 percent year-over-year versus the consensus 5 percent base), and the loss-ratio compression to 71,8 percent in Q1 2026 was 30 basis-points ahead of consensus 72,1 percent. Applying a peer-blended fair-multiple of 12–14x forward-earnings (still discounted to specialty-insurance-and-pet-insurance peers at 15–25x to reflect the cyclical-overhang and CEO-transition uncertainty) to a base-case fiscal-2027 EPS of approximately 5,50 USD produces a 12–18-month fair-value range of approximately 66–77 USD per share — implying approximately 195–245 percent upside from the 22,33 USD entry-price. The bear-case scenario (veterinary-cost-inflation re-acceleration, loss-ratio re-expansion above 73 percent, pet-policy-growth stalls) supports a 18–25 USD fair-value range, providing approximately 0–15 percent downside-to-slight-upside. The bull-case scenario (loss-ratio compresses to 69 percent by 2027, ARPP growth accelerates to 10 percent, pet-policy-growth exceeds 13 percent) supports a 85–95 USD price range.
🗓️ Next 3 Catalyst Dates
-
2026 Q3:
Q2 2026 earnings release (early August 2026). Watch-items: loss-ratio for the quarter (must trend toward 71,5–72 percent versus consensus 72,3 percent), pet-policy-net-additions (target 35.000–45.000 net-new versus consensus 30.000), ARPP-progression (target 81 USD per month versus consensus 80 USD), churn-rate-progression (target 11,5 percent annualized versus consensus 11,8 percent). A beat on loss-ratio and pet-addition would re-rate the stock toward 32–38 USD.
-
2026 Q4:
Q3 2026 earnings release (early November 2026) and full-fiscal-year-2026 guidance reaffirmation or update. Watch-items: Q3 loss-ratio (target 71,2–71,8 percent), Q4 pet-policy-addition-pace heading into the year-end period (target 30.000+ net-new), any updated commentary on fiscal-2027 loss-ratio trajectory (consensus is for 71 percent fiscal-2027, but management could guide tighter at 70,5 percent), and any commentary on capital-allocation including potential share-buyback or strategic-partnership announcements. A reassuring Q3 result plus tightened fiscal-2027 loss-ratio guidance would unlock 40–50 USD price-range.
-
2027 Q1:
Fiscal-2026 full-year results (mid-February 2027) plus fiscal-2027 guidance. Watch-items: full-fiscal-2026 EPS versus the consensus 4,31 USD bar, fiscal-2027 EPS guidance-range (consensus is for approximately 5,50 USD, but a bullish management guidance of 5,80–6,20 USD would be the canonical re-rating catalyst), fiscal-2027 loss-ratio guidance (target 70,5 percent or below), and any commentary on international-expansion (Germany and Switzerland subsidiary scaling, potential UK-market re-entry). A strong fiscal-2027 guidance would unlock the 55–70 USD fair-value range.
💬 Daniel's Take
Trupanion is a structurally-recovering subscription-insurance-compounder with veterinary-cost-inflation tailwind compression, direct-pay-veterinary-software competitive moat, lifetime-value-per-pet at all-time highs of approximately 1.500–1.700 USD, and a deep-cyclical-trough forward-earnings-multiple of 5,2x that materially under-prices the structural recovery already underway. The thesis is genuinely binary on the loss-ratio trajectory: if the Q1 2026 trend (loss-ratio at 71,8 percent, churn at 11,5 percent, ARPP at 79 USD) extends through fiscal-2026 and fiscal-2027 as management has guided, the fair-value is materially above the 22,33 USD entry; if veterinary-cost-inflation re-accelerates or the rate-action-cycle damages pet-policy-base more durably, the fair-value compresses toward the 18–25 USD bear-case range.
Position-sizing: 1,5–2,0 percent allocation in a thematic-quality-cyclical-recovery sleeve, suitable for investors with 18–36 month patience and tolerance for quarterly-loss-ratio-volatility. The 22,33 USD entry-price is approximately 40 percent above the June 2024 low of 16,20 USD and approximately 75 percent below the late-2021 peak of approximately 90 USD. Sizing-up zones are 18–20 USD on any short-term-multiple compression unrelated to operating-fundamentals (which would imply 4,2–4,7x forward-earnings on the conservatively-assumed loss-ratio trajectory). The structural-bear scenarios (veterinary-cost re-acceleration, US-penetration-stall, CEO-transition-cultural-erosion) are real but mitigated by the direct-pay-veterinary-software moat, the PRIMECAP-Akre institutional-conviction-base, and the deep cyclical-trough valuation that requires only modest operating-recovery to deliver high-conviction multi-bagger return profile.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
Where can I buy Trupanion?
Compare top-rated brokers — low fees, trusted providers, fully regulated.